drugset / Trial / NCT02797171
Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will evaluate the safety, pharmacokinetics, and antiviral activity of VRC-HIVMAB060-00-AB (VRC01) and VRC-HIVMAB080-00-AB (VRC01LS) in the serum and mucosa of healthy, HIV-uninfected adults.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2019-06-05
- Completion
- 2019-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VRC01 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | VRC01 | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | VRC01LS | Monoclonal antibody | 30 mg/kg | Intravenous |